The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

Cover Page

Cite item

Full Text

Abstract

The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a poor prognostic factor for HR+ HER2- metastatic breast cancer. Alpelisib demonstrates efficacy in patients with PIK3CA mutation, but treatment might be associated with adverse events that include rash. All-grade rash was reported in 35.6% patients in SOLAR-1 trial (n=284). According to the published real-world data, for Russian population (n=19) all-grade rash was reported for 37% patients. The consensus contains practical recommendation on management of patients with rash of different grade.

About the authors

Irena L. Shlivko

Privolzhsky Research Medical University

Email: irshlivko@gmail.com
ORCID iD: 0000-0001-7253-7091

D. Sci. (Med.)

Russian Federation, Nizhny Novgorod

Oxana E. Garanina

Privolzhsky Research Medical University

Email: oksanachekalkina@yandex.ru
ORCID iD: 0000-0002-7326-7553

Cand. Sci. (Med.)

Russian Federation, Nizhny Novgorod

Elena V. Artamonova

Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University; Vladimirsky Moscow Regional Research Clinical Institute

Author for correspondence.
Email: artamonovae@mail.ru
ORCID iD: 0000-0001-7728-9533

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Inna P. Ganshina

Blokhin National Medical Research Center of Oncology

Email: ganshinainna77@mail.ru
ORCID iD: 0000-0002-0105-9376

Cand. Sci. (Med.)

Russian Federation, Moscow

Liudmila G. Zhukova

Loginov Moscow Clinical Scientific Center

Email: zhukova.lyudmila008@gmail.com
ORCID iD: 0000-0003-4848-6938

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Irina A. Koroleva

Medical University "Reaviz"

Email: korolevaia_samara@mail.ru
ORCID iD: 0000-0002-1836-0851

D. Sci. (Med.), Prof.

Russian Federation, Samara

Anna V. Michenko

Central State Medical Academy of the President of the Russian Federation

Email: amichenko@mail.ru
ORCID iD: 0000-0002-2985-5729

Cand. Sci. (Med.)

Russian Federation, Moscow

Tatiana Yu. Semiglazova

Petrov National Medicine Research Center of Oncology; Mechnikov North-Western State Medical University

Email: tsemiglazova@mail.ru
ORCID iD: 0000-0002-4305-6691

D. Sci. (Med.), Assoc. Prof.

Russian Federation, Saint Petersburg

Daria A. Filonenko

Loginov Moscow Clinical Scientific Center

Email: shubina_d@mail.ru
ORCID iD: 0000-0002-7224-3111

Cand. Sci. (Med.)

Russian Federation, Moscow

References

  1. Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018;119(6):4287-92. doi: 10.1002/jcb.26687
  2. Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. doi: 10.1186/s13058-020-01284-9
  3. Signorovitch J, Andre F, Wang R, et al. PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/human endocrine receptor negative (HER2-) metastatic breast cancer (mBC): A meta-analysis of published clinical trials. J Clin Oncol. 2020;38(15 Suppl.):1069. doi: 10.1200/JCO.2020.38.15_suppl.1069
  4. Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-40. doi: 10.1056/NEJMoa1813904
  5. Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001-10. doi: 10.1016/j.annonc.2020.05.001
  6. Филоненко Д.А., Ибрагимова Т.М., Польшина Н.И., и др. Таргетная терапия люминального HER2-негативного метастатического рака молочной железы c мутацией PIK3CA: комбинация алпелисиба с фулвестрантом в реальной клиничес- кой практике. Медицинский совет. 2021;20:113-20 [Filonenko DA, Ibragimova TM, Polshina NI, et al. Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice. Meditsinskiy sovet = Medical Council. 2021;20:113-20 (in Russian)].
  7. Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30(Suppl. 10):x21-6. doi: 10.1093/annonc/mdz440
  8. Calautti E, Li J, Saoncella S, et al. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem. 2005;280(38):32856-65. doi: 10.1074/jbc.M506119200
  9. Wang DG, Barrios DM, Blinder VS, et al. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat. 2020;183(1):227-37. doi: 10.1007/s10549-020-05726-y
  10. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489-98. doi: 10.1016/S1470-2045(21)00034-6
  11. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021:S0923-7534(21)04498-7. doi: 10.1016/j.annonc.2021.09.019
  12. Атопический дерматит. Клинические рекомендации. 2020. Режим доступа: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Ссылка активна на 15.11.2021 [Atopic dermatitis. Clinical Guidelines. 2020. Available at: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Accessed: 15.11.2021 (in Russian)].
  13. Dreno B, Bensadoun RJ, Humbert P, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol. 2013;27(9):1071-80. doi: 10.1111/jdv.12082
  14. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, et al. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073-81. doi: 10.4239/wjd.v6.i8.1073
  15. Мазурина Н.В., Артамонова Е.В., Белоярцева М.Ф., и др. Консенсус по профилактике и коррекции гипергликемии у пациентов, получающих терапию препаратом алпелисиб. Современная Онкология. 2020;22(4):56-9 [Mazurina NV, Artamonova EV, Beloyartseva MF, et al. The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib. Journal of Modern Oncology. 2020;22(4):56-9 (in Russian)]. doi: 10.26442/18151434.2020.4.200566
  16. Синдром Стивенса–Джонсона. Клинические рекомендации Российского общества дерматовенерологов и косметологов. 2020. Режим доступа: https://www.rodv.ru/klinicheskie-rekomendacii/ Ссылка активна на 15.11.2021 [Stevens–Johnson Syndrome. Clinical Guidelines of the Russian Society of Dermatovenerologists and cosmetologists. 2020. Available at: https://www.rodv.ru/klinicheskie-rekomendacii. Accessed: 15.11.2021 (in Russian)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Estimation of body surface area: "rule of nine".

Download (95KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies